Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study.
extracorporeal membrane oxygenation
shock, cardiogenic
Journal
Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
10
10
2020
medline:
12
10
2021
entrez:
9
10
2020
Statut:
ppublish
Résumé
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used to treat cardiogenic shock. However, VA-ECMO might hamper myocardial recovery. The Impella unloads the left ventricle. This study aimed to evaluate whether left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO was associated with lower mortality. Data from 686 consecutive patients with cardiogenic shock treated with VA-ECMO with or without left ventricular unloading using an Impella at 16 tertiary care centers in 4 countries were collected. The association between left ventricular unloading and 30-day mortality was assessed by Cox regression models in a 1:1 propensity score-matched cohort. Left ventricular unloading was used in 337 of the 686 patients (49%). After matching, 255 patients with left ventricular unloading were compared with 255 patients without left ventricular unloading. In the matched cohort, left ventricular unloading was associated with lower 30-day mortality (hazard ratio, 0.79 [95% CI, 0.63-0.98]; In this international, multicenter cohort study, left ventricular unloading was associated with lower mortality in patients with cardiogenic shock treated with VA-ECMO, despite higher complication rates. These findings support use of left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO and call for further validation, ideally in a randomized, controlled trial.
Sections du résumé
BACKGROUND
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used to treat cardiogenic shock. However, VA-ECMO might hamper myocardial recovery. The Impella unloads the left ventricle. This study aimed to evaluate whether left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO was associated with lower mortality.
METHODS
Data from 686 consecutive patients with cardiogenic shock treated with VA-ECMO with or without left ventricular unloading using an Impella at 16 tertiary care centers in 4 countries were collected. The association between left ventricular unloading and 30-day mortality was assessed by Cox regression models in a 1:1 propensity score-matched cohort.
RESULTS
Left ventricular unloading was used in 337 of the 686 patients (49%). After matching, 255 patients with left ventricular unloading were compared with 255 patients without left ventricular unloading. In the matched cohort, left ventricular unloading was associated with lower 30-day mortality (hazard ratio, 0.79 [95% CI, 0.63-0.98];
CONCLUSIONS
In this international, multicenter cohort study, left ventricular unloading was associated with lower mortality in patients with cardiogenic shock treated with VA-ECMO, despite higher complication rates. These findings support use of left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO and call for further validation, ideally in a randomized, controlled trial.
Identifiants
pubmed: 33032450
doi: 10.1161/CIRCULATIONAHA.120.048792
pmc: PMC7688081
doi:
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2095-2106Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Références
ASAIO J. 2020 May;66(5):497-503
pubmed: 31335363
Curr Opin Crit Care. 2019 Aug;25(4):391-396
pubmed: 31135393
Am J Cardiol. 2017 Mar 15;119(6):845-851
pubmed: 28040188
Catheter Cardiovasc Interv. 2019 Jul 1;94(1):29-37
pubmed: 31104355
N Engl J Med. 1999 Aug 26;341(9):625-34
pubmed: 10460813
N Engl J Med. 2018 Nov 1;379(18):1699-1710
pubmed: 30145971
Int J Cardiol. 2020 Aug 1;312:16-21
pubmed: 32057479
JACC Heart Fail. 2018 Dec;6(12):1035-1043
pubmed: 30497643
Circulation. 2019 Mar 5;139(10):1249-1258
pubmed: 30586755
J Am Coll Cardiol. 2019 May 14;73(18):2355-2357
pubmed: 31072581
J Am Coll Cardiol. 2018 Jul 31;72(5):569-580
pubmed: 30056830
Circulation. 2018 Nov 13;138(20):2298-2300
pubmed: 30571518
ASAIO J. 2019 Jan;65(1):21-28
pubmed: 29489461
J Clin Med. 2020 Mar 03;9(3):
pubmed: 32138283
Circulation. 2020 Jan 28;141(4):273-284
pubmed: 31735078
JAMA. 2020 Feb 25;323(8):734-745
pubmed: 32040163
ASAIO J. 2018 Jul/Aug;64(4):497-501
pubmed: 29076945
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Circ Heart Fail. 2020 Mar;13(3):e005853
pubmed: 32164431
Ann Thorac Surg. 2014 Feb;97(2):610-6
pubmed: 24210621
J Clin Med. 2020 Mar 28;9(4):
pubmed: 32231121
N Engl J Med. 2012 Oct 4;367(14):1287-96
pubmed: 22920912
Eur Heart J. 2019 Aug 21;40(32):2671-2683
pubmed: 31274157
Circ Cardiovasc Qual Outcomes. 2019 Mar;12(3):e005618
pubmed: 30879324
J Am Coll Cardiol. 2019 Feb 19;73(6):654-662
pubmed: 30765031
Eur J Heart Fail. 2017 Mar;19(3):404-412
pubmed: 27709750
Artif Organs. 2019 Feb;43(2):125-131
pubmed: 30216467
Ann Cardiothorac Surg. 2019 Jan;8(1):66-75
pubmed: 30854314
Perfusion. 2019 Sep;34(6):453-459
pubmed: 30736721